Omar Eton, MD

Associate Professor, Medicine

(617) 638-7520
820 Harrison Ave

Biography

Expertise includes: Preclinical to clinical transitions in Oncology; Phase 1,2,3,… oncology drug development from blank concept page to IRB protocol approval and successful trial execution and final published manuscript; Melanoma; Tyrosine kinase inhibitors; Tumor immunology; Endocrine tumors; and GI tumors. Interests include nanocarriers and cutting edge discovery agents heading to the clinic.

Other Positions

  • Active Staff Privileges, Medicine, Boston Medical Center

Education

  • New York University School of Medicine, MD
  • Harvard College, AB

Publications

  • Published on 9/1/2017

    White PS, Pudusseri A, Lee SL, Eton O. Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAFV600E Mutated Papillary Thyroid Cancer: Two Case Reports. Thyroid. 2017 Sep; 27(9):1201-1205. PMID: 28805135.

    Read at: PubMed
  • Published on 10/1/2012

    Fonkem E, Uhlmann EJ, Floyd SR, Mahadevan A, Kasper E, Eton O, Wong ET. Melanoma brain metastasis: overview of current management and emerging targeted therapies. Expert Rev Neurother. 2012 Oct; 12(10):1207-15. PMID: 23082737.

    Read at: PubMed
  • Published on 8/19/2010

    Macarulla T, Cervantes A, Elez E, Rodríguez-Braun E, Baselga J, Roselló S, Sala G, Blasco I, Danaee H, Lee Y, Ecsedy J, Shinde V, Chakravarty A, Bowman D, Liu H, Eton O, Fingert H, Tabernero J. Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics. Mol Cancer Ther. 2010 Oct; 9(10):2844-52. PMID: 20724522.

    Read at: PubMed
  • Published on 7/7/2010

    Dees EC, Infante JR, Cohen RB, O'Neil BH, Jones S, von Mehren M, Danaee H, Lee Y, Ecsedy J, Manfredi M, Galvin K, Stringer B, Liu H, Eton O, Fingert H, Burris H. Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2011 Apr; 67(4):945-54. PMID: 20607239.

    Read at: PubMed
  • Published on 1/29/2010

    Eton O, Ross MI, East MJ, Mansfield PF, Papadopoulos N, Ellerhorst JA, Bedikian AY, Lee JE. Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma. J Transl Med. 2010; 8:9. PMID: 20109236.

    Read at: PubMed
  • Published on 8/1/2009

    Lynch TJ, Fenton D, Hirsh V, Bodkin D, Middleman EL, Chiappori A, Halmos B, Favis R, Liu H, Trepicchio WL, Eton O, Shepherd FA. A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer. J Thorac Oncol. 2009 Aug; 4(8):1002-9. PMID: 19633475.

    Read at: PubMed
  • Published on 2/1/2009

    Kim KB, Legha SS, Gonzalez R, Anderson CM, Johnson MM, Liu P, Papadopoulos NE, Eton O, Plager C, Buzaid AC, Prieto VG, Hwu WJ, Frost AM, Alvarado G, Hwu P, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Benjamin RS, Bedikian AY. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res. 2009 Feb; 19(1):42-9. PMID: 19430405.

    Read at: PubMed
  • Published on 8/19/2008

    Kim KB, Eton O, Davis DW, Frazier ML, McConkey DJ, Diwan AH, Papadopoulos NE, Bedikian AY, Camacho LH, Ross MI, Cormier JN, Gershenwald JE, Lee JE, Mansfield PF, Billings LA, Ng CS, Charnsangavej C, Bar-Eli M, Johnson MM, Murgo AJ, Prieto VG. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer. 2008 Sep 2; 99(5):734-40. PMID: 18728664.

    Read at: PubMed
  • Published on 8/1/2008

    Hwang CS, Prieto VG, Diwan AH, Lizee G, Ellerhorst JA, Ekmekcioglu S, Liu P, Eton O, Kinney SA, Grimm EA, Hwu P, Kim KB. Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment. Melanoma Res. 2008 Aug; 18(4):241-5. PMID: 18626307.

    Read at: PubMed
  • Published on 5/1/2006

    Wyman K, Atkins MB, Prieto V, Eton O, McDermott DF, Hubbard F, Byrnes C, Sanders K, Sosman JA. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer. 2006 May 1; 106(9):2005-11. PMID: 16565971.

    Read at: PubMed

View 40 more publications: View full profile at BUMC

View all profiles